Title:
被験者の特定のグループを処置する方法において使用するためのＰＣＳＫ９に対するヒト抗体
Document Type and Number:
Japanese Patent JP7140800
Kind Code:
B2
Abstract:
The present invention relates to methods for treating diseases or conditions in which proprotein convertase subtilisin/kexin type 9 (PCSK9) expression or activity causes an impact by administration of PCSK9-specific antibodies or antigen-binding fragments thereof and preferably by additional administration of an inhibitor of 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoA reductase). The present invention further relates to PCSK9-specific antibodies or antigen-binding fragments thereof for use in the treatment of diseases or conditions in which PCSK9 expression or activity causes an impact. The present invention also relates to articles of manufacture comprising packaging material, PCSK9-specific antibodies or antigen-binding fragments thereof, and a label or packaging insert indicating which groups of patients can be treated with said antibodies or fragments, which groups of patients must not be treated with said antibodies or fragments, and which dosage regimen should be used. The present invention further relates to methods of testing the efficacy of PCSK9-specific antibodies or antigen-binding fragments thereof for the treatment of certain diseases or conditions and for the treatment of specific sub-groups of patients.
More Like This:
| JP2008179639 | C-CCKR-5, CC-CHEMOKINES RECEPTOR, DERIVATIVES THEREOF, AND THEIR USES |
| WO/2005/000900 | TREATMENT WITH ANTI-VEGF ANTIBODIES |
| JP5409952 | Sclerostin binding agent |
Inventors:
Corinne Annotin
Laurence Besakki
Woomesh Saudari
Laurence Besakki
Woomesh Saudari
Application Number:
JP2020114604A
Publication Date:
September 21, 2022
Filing Date:
July 02, 2020
Export Citation:
Assignee:
REGENERON PHARMACEUTICALS, INC.
International Classes:
A61K39/395; A61P3/06; C07K16/40
Foreign References:
| WO2010077854A1 |
Attorney, Agent or Firm:
Junji Yuda
Noriyuki Takebayashi
Noriyuki Takebayashi